Hematology

Currently, ocifisertib is being evaluated in a phase 1b and 2 trial to confirm the safety and tolerability profiles in patients with acute myeloid leukemia.

Certain patients may present asymptomatically, affecting treatment options.

The oral therapy is available through a REMS program.

These disorders can be fatal, making pharmacists’ role in detection crucial.

The results indicate promising rates of complete response, manageable adverse events, and dose-dependent exposure in both dose groups.

Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.

In a study, nipocalimab helped more than 50% of patients with high-risk of hemolytic disease of the fetus and newborn achieve a safe live birth.

In November 2023, the FDA announced an investigation of CAR T-cell therapy based on several reported secondary T-cell malignancies.

The model was designed to help improve health outcomes, improve access to care, and lower costs for gene therapy.

Approximately 41% of enrolled patients responded to NX-2127, and the BTK degrader overcame resistance to nearly all BTK mutations that were identified to cause resistance.

According to the authors, the test has promise in guiding treatment but needs further refining to obtain information beyond molecular subtyping.

The findings suggest that further research on additional intervention methods and expanding access to hydroxyurea in Africa could benefit young patients with sickle cell disease.

Less manufacturing time could be the difference between a patient receiving this life-saving therapy vs not.

The MRD-guided treatment approach has a significant advantage over chemotherapy.

It can also help identify patients who would benefit from disease-specific therapies.

Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.

There is a significant efficacy-effectiveness gap in standard-of-care regimens.

Further policy changes to promote gender equity may be needed.

PTX-252 is a novel molecular drug designed to increase cancer cells' sensitivity to chemotherapy in the treatment of acute myeloid leukemia.

Presentations detail clinical trial results and focus on drugs in the pipeline.

2023 was an impactful year for the field of oncology pharmacy.

Not only were individuals with BMIs of 30 and higher likely to have MGUS, but those who reported heavy smoking and short sleep were also more likely to have detectable levels of MGUS.

In addition, patients who were treated with liso-cel therapy had a higher average life expectancy and QALYs, compared to those who were treated with standard care.

Compared to standard of care TKIs, asciminib also presented favorable safety and tolerability profiles with fewer reported AEs among patients.

The study results also demonstrated isatuximab had safety and tolerability profiles that were consistent with other clinical trials.

Nearly 75% of patients who had an initial complete response with mosunetuzumab maintained that complete response after 3 years.

Eliminating certain factors within the GRN resulted in the network shutting down, potentially leading to cancer cell death due to an inability to replicate, according to the study authors.

New CAR T development method infuses immune T cells from healthy people into patients to improve outcomes.

The investigators advise that the use of bendamustine should be avoided when possible in patients with refractory LBCL who are potential candidates for CAR T-cell therapy.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.